BioCentury | May 19, 2020
Finance

May 19 Quick Takes: Cowen closes $493M fund; plus Guangzhou BeBetter, Fountain Therapeutics, Amplyx, ChromaCode, Applied Molecular

Cowen raises $493M life sciences fund   Cowen Healthcare Investments closed its third life sciences fund at $493 million to invest in biopharma, diagnostics and digital health. LPs in Cowen Healthcare Investments III include institutional...
BC Extra | Sep 16, 2019
Company News

Sept. 16 Company Quick Takes: FDA accepts Seattle Genetics' BLA; plus Akynzeo, Purdue, Amplyx, Abbott-Sanofi

FDA to review enfortumab vedotin  Seattle Genetics Inc. (NASDAQ:SGEN) and partner Astellas Pharma Inc. (JASDAQ:4503) said FDA has accepted a BLA and granted Priority Review to enfortumab vedotin for locally advanced or metastatic urothelial cancer....
BC Extra | Jan 9, 2018
Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
BC Week In Review | Nov 30, 2017
Clinical News

Amplyx reports Phase I data for APX001 in fungal infections

In October, Amplyx Pharmaceuticals Inc. (San Diego, Calif.) reported data from two Phase I trials in 166 healthy volunteers showing that oral and IV APX001 were well tolerated at all doses tested. Additionally, the company...
BioCentury | Aug 4, 2017
Finance

Fungal flexibility

Undisclosed first-in-human safety data persuaded a host of new investors to infuse Amplyx Pharmaceuticals Inc. with enough cash to pursue multiple indications for its broad-spectrum antifungal, APX001. On Aug. 2, the biotech raised $67 million...
BC Week In Review | Aug 4, 2017
Financial News

Amplyx raises $67M in series C

Anti-infectives company Amplyx Pharmaceuticals Inc. (San Diego, Calif.) raised $67 million in an oversubscribed series C round led by Sofinnova Ventures on Aug. 2. Also participating were new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas...
BC Extra | Aug 2, 2017
Financial News

Amplyx raises $67M in series C

Anti-infectives company Amplyx Pharmaceuticals Inc. (San Diego, Calif.) raised $67 million in an oversubscribed series C round led by Sofinnova Ventures. Also participating were new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas Capital, and existing...
BC Extra | Jan 14, 2017
Company News

Management tracks

Rare diseases company Swedish Orphan Biovitrum AB (SSE:SOBI) said CEO Geoffrey McDonough will leave the company on July 1. The company is searching for a replacement. The company also named Armin Reininger SVP and head...
BC Week In Review | Sep 19, 2016
Clinical News

IV APX001: Phase I started

Amplyx began a double-blind, placebo-controlled, dose-escalation, European Phase I trial to evaluate single and multiple doses of IV APX001 in about 80 healthy volunteers. The company plans to begin Phase I testing of oral APX001...
BC Week In Review | Jun 20, 2016
Clinical News

APX001 regulatory update

Amplyx Pharmaceuticals Inc. , San Diego, Calif.   Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan   Product: APX001   Business: Infectious   FDA granted Qualified Infectious Disease Product (QIDP) designation to APX001 from Amplyx to treat 3...
Items per page:
1 - 10 of 18
BioCentury | May 19, 2020
Finance

May 19 Quick Takes: Cowen closes $493M fund; plus Guangzhou BeBetter, Fountain Therapeutics, Amplyx, ChromaCode, Applied Molecular

Cowen raises $493M life sciences fund   Cowen Healthcare Investments closed its third life sciences fund at $493 million to invest in biopharma, diagnostics and digital health. LPs in Cowen Healthcare Investments III include institutional...
BC Extra | Sep 16, 2019
Company News

Sept. 16 Company Quick Takes: FDA accepts Seattle Genetics' BLA; plus Akynzeo, Purdue, Amplyx, Abbott-Sanofi

FDA to review enfortumab vedotin  Seattle Genetics Inc. (NASDAQ:SGEN) and partner Astellas Pharma Inc. (JASDAQ:4503) said FDA has accepted a BLA and granted Priority Review to enfortumab vedotin for locally advanced or metastatic urothelial cancer....
BC Extra | Jan 9, 2018
Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
BC Week In Review | Nov 30, 2017
Clinical News

Amplyx reports Phase I data for APX001 in fungal infections

In October, Amplyx Pharmaceuticals Inc. (San Diego, Calif.) reported data from two Phase I trials in 166 healthy volunteers showing that oral and IV APX001 were well tolerated at all doses tested. Additionally, the company...
BioCentury | Aug 4, 2017
Finance

Fungal flexibility

Undisclosed first-in-human safety data persuaded a host of new investors to infuse Amplyx Pharmaceuticals Inc. with enough cash to pursue multiple indications for its broad-spectrum antifungal, APX001. On Aug. 2, the biotech raised $67 million...
BC Week In Review | Aug 4, 2017
Financial News

Amplyx raises $67M in series C

Anti-infectives company Amplyx Pharmaceuticals Inc. (San Diego, Calif.) raised $67 million in an oversubscribed series C round led by Sofinnova Ventures on Aug. 2. Also participating were new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas...
BC Extra | Aug 2, 2017
Financial News

Amplyx raises $67M in series C

Anti-infectives company Amplyx Pharmaceuticals Inc. (San Diego, Calif.) raised $67 million in an oversubscribed series C round led by Sofinnova Ventures. Also participating were new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas Capital, and existing...
BC Extra | Jan 14, 2017
Company News

Management tracks

Rare diseases company Swedish Orphan Biovitrum AB (SSE:SOBI) said CEO Geoffrey McDonough will leave the company on July 1. The company is searching for a replacement. The company also named Armin Reininger SVP and head...
BC Week In Review | Sep 19, 2016
Clinical News

IV APX001: Phase I started

Amplyx began a double-blind, placebo-controlled, dose-escalation, European Phase I trial to evaluate single and multiple doses of IV APX001 in about 80 healthy volunteers. The company plans to begin Phase I testing of oral APX001...
BC Week In Review | Jun 20, 2016
Clinical News

APX001 regulatory update

Amplyx Pharmaceuticals Inc. , San Diego, Calif.   Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan   Product: APX001   Business: Infectious   FDA granted Qualified Infectious Disease Product (QIDP) designation to APX001 from Amplyx to treat 3...
Items per page:
1 - 10 of 18